

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM817627

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Eyepoint Pharmaceuticals US, Inc.	FORMERLY pSivida US, Inc.	06/13/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Alimera Sciences, Inc.		
Street Address:	6310 Town Square		
Internal Address:	Suite 400		
City:	Alpharetta		
State/Country:	GEORGIA		
Postal Code:	30005		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	5763976	YUTIQ	
Registration Number:	6153947	YUTIQ	
CORRESPONDENCE DATA			
Fax Number:	4048538806		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	404-853-8926		
Email:	patentdocket@eversheds-sutherland.com		
Correspondent Name:	Jeremy D. Spier		
Address Line 1:	999 Peachtree Street, NE, Suite 2300		
Address Line 4:	Atlanta, GEORGIA 30309		
ATTORNEY DOCKET NUMBER:	35962-0154		
NAME OF SUBMITTER:	Jeremy D. Spier		
SIGNATURE:	/JDS/		
DATE SIGNED:	06/15/2023		
Total Attachments: 3			
source=Trademark Assignment (EyePoint - Alimera) signed by EyePoint 06-13-23#page1.tif			
source=Trademark Assignment (EyePoint - Alimera) signed by EyePoint 06-13-23#page2.tif			

CH \$65.00 5763976

TRADEMARK ASSIGNMENT AGREEMENT

This **TRADEMARK ASSIGNMENT** (“Assignment”) is hereby entered into on the 13th day of June, 2023 (the “Effective Date”), between EYEPOINT PHARMACEUTICALS, INC., EYEPOINT PHARMACEUTICALS US, INC. (formerly known as pSivida US, Inc.) (collectively “Assignor”), each a Delaware corporation having a principal place of business 480 Pleasant Street, Suite C-400, Watertown, MA 02472, and ALIMERA SCIENCES, INC., (“Assignee”), a Delaware corporation having a principal place of business at 6310 Town Square, Suite 400, Alpharetta, GA 30005.

WHEREAS, pursuant to the Products Rights Agreement executed May 17, 2023 (the “PRA”), Assignor agreed to assign and transfer all of its right, title, and interest in and to the U.S. and foreign trademark registrations set forth in Schedule A (the “Marks”) to Assignee; and

WHEREAS, Assignee is desirous of acquiring all right, title, and interest in and to the Marks, including any and all common law rights and associated goodwill of the Marks, and recording such with the appropriate authorities, entities, and agencies in any and all jurisdictions, in accordance with the PRA.

NOW, THEREFORE, for good and valuable consideration paid by Assignee to Assignor, the receipt and sufficiency of which is hereby acknowledged, in accordance with and subject to the PRA, Assignor hereby assigns and transfers to Assignee all right, title, and interest in and to the Marks, together with all of the goodwill of the business symbolized by the Marks and the right to recover damages, profits, royalties, and all other remedies for all past and future infringements thereof.

[Signature Page Follows]

In witness whereof, the parties have duly executed and delivered this Assignment, as of the Effective Date.

EyePoint Pharmaceuticals, Inc.



Signature

Ron Honig

Name

Chief Legal Officer

Title

EyePoint Pharmaceuticals US, Inc. (f/k/a pSivida US, Inc.)



Signature


Ron Honig

Name

Chief Legal Officer

Title

Alimera Sciences, Inc.



Signature

Christopher S. Visick

Name

Vice President, General Counsel and Secretary

Title

SCHEDULE A:

Mark	Country	Registration No.	Date of Registration	Owner
YUTIQ	EU -- International Registration	1,336,736	Dec. 9, 2016	pSivida US, Inc. (nka EyePoint Pharmaceuticals US, Inc.)
YUTIQ	UK -- International Registration	1,336,736	Dec. 9, 2016	pSivida US, Inc. (nka EyePoint Pharmaceuticals US, Inc.)
YUTIQ	Mexico	2,387,650	Jan 3, 2022	EyePoint Pharmaceuticals US, Inc.
YUTIQ	Mexico	2,387,653	Jan 3, 2022	EyePoint Pharmaceuticals US, Inc.
YUTIQ	US	5,763,976	May 28, 2019	EyePoint Pharmaceuticals US, Inc.
YUTIQ (and Design) 	US	6,153,947	September 15, 2020	EyePoint Pharmaceuticals US, Inc.